Volume 38 Issue 8
Aug.  2022
Turn off MathJax
Article Contents
SHEN Hong, ZHU Lei, ZHANG Lu. Exploration of Treatment Strategies with Integrated Traditional Chinese and Western Medicine for Crohn's Disease under the Background of Biological Agents[J]. Journal of Nanjing University of traditional Chinese Medicine, 2022, 38(8): 739-742. doi: 10.14148/j.issn.1672-0482.2022.0739
Citation: SHEN Hong, ZHU Lei, ZHANG Lu. Exploration of Treatment Strategies with Integrated Traditional Chinese and Western Medicine for Crohn's Disease under the Background of Biological Agents[J]. Journal of Nanjing University of traditional Chinese Medicine, 2022, 38(8): 739-742. doi: 10.14148/j.issn.1672-0482.2022.0739

Exploration of Treatment Strategies with Integrated Traditional Chinese and Western Medicine for Crohn's Disease under the Background of Biological Agents

doi: 10.14148/j.issn.1672-0482.2022.0739
  • Received Date: 2021-03-16
    Available Online: 2022-08-05
  • Crohn' s disease (CD) is a chronic, progressive and disabling disease, which seriously affects the quality of life of patients. In recent years, with the continuous listing of biological agents in China, the treatment of CD has entered the era of biological agents, which has brought about continuous upgrading of treatment goals and changes in treatment strategies. Integrated traditional Chinese and western medicine has provided optimized treatment methods for CD patients, so how to make use of the advantages of integrated traditional Chinese and western medicine in the background of biological agents is a importent clinical issue. This article elaborates the treatment strategy for CD under the background of biological agents. Clinically, according to the different clinical manifestations of CD, it can be treated from different perspectives of "Li", "Yang", "Yong", "Luo" and "Lao", from the prevention and treatment of infection, anti-fibrosis, reduction of complications, and improvement of malnutrition In order to adapt to the change of treatment goals and improve clinical efficacy.

     

  • loading
  • [1]
    NG SC, SHI HY, HAMIDI N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies[J]. Lancet, 2017, 390(10114): 2769-2778. doi: 10.1016/S0140-6736(17)32448-0
    [2]
    ZHAO J, NG SC, LEI Y, et al. First prospective, population-based inflammatory bowel disease incidence study in mainland of China[J]. Inflamm Bowel Dis, 2013: 1.
    [3]
    ZENG ZR, ZHU ZH, YANG YY, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population-based study[J]. J Gastroenterol Hepatol, 2013, 28(7): 1148-1153. doi: 10.1111/jgh.12164
    [4]
    YANG H, LI YM, WU W, et al. The incidence of inflammatory bowel disease in Northern China: A prospective population-based study[J]. PLoS One, 2014, 9(7): e101296. doi: 10.1371/journal.pone.0101296
    [5]
    PEYRIN-BIROULET L, SANDBORN W, SANDS BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target[J]. Am J Gastroenterol, 2015, 110(9): 1324-1338. doi: 10.1038/ajg.2015.233
    [6]
    PEDERSEN J. Inflammatory pathways of importance for management of inflammatory bowel disease[J]. World J Gastroenterol, 2014, 20(1): 64. doi: 10.3748/wjg.v20.i1.64
    [7]
    MARAFINI I, SEDDA S, DINALLO V, et al. Inflammatory cytokines: From discoveries to therapies in IBD[J]. Expert Opin Biol Ther, 2019, 19: 1207-1217. doi: 10.1080/14712598.2019.1652267
    [8]
    TORRES J, BONOVAS S, DOHERTY G, et al. ECCO guidelines on therapeutics in Crohn's disease: Medical treatment[J]. J Crohn's Colitis, 2020, 14(1): 4-22. doi: 10.1093/ecco-jcc/jjz180
    [9]
    TURNER D, RICCIUTO A, LEWIS A, et al. STRIDE-Ⅱ: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD[J]. Gastroenterology, 2021, 160(5): 1570-1583. doi: 10.1053/j.gastro.2020.12.031
    [10]
    YANG E, PANACCIONE N, WHITMIRE N, et al. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease[J]. Aliment Pharmacol Ther, 2020, 51(11): 1031-1038.
    [11]
    PRIVITERA G, ONALI S, PUGLIESE D, et al. Dual targeted therapy: A possible option for the management of refractory inflammatory bowel disease[J]. J Crohn's Colitis, 2021, 15(2): 335-339. doi: 10.1093/ecco-jcc/jjaa149
    [12]
    CASTIGLIONE F, IMPERATORE N, TESTA A, et al. One-year clinical outcomes with biologics in Crohn's disease: transmural healing compared with mucosal or no healing[J]. Aliment Pharmacol Ther, 2019, 49(8): 1026-1039.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (124) PDF downloads(15) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return